Mesothelin-Targeted Therapy

Mesothelin-targeted therapy is a class of experimental cancer treatments that attack tumor cells displaying a protein called mesothelin on their surface. Because mesothelioma, ovarian cancer, and some lung and pancreatic cancers express high levels of mesothelin while most healthy tissues do not, this protein serves as a 'flag' that allows drugs, antibodies, or engineered immune cells to find and destroy cancer cells more selectively. Approaches include antibody-drug conjugates, immunotoxins, bispecific antibodies, CAR T-cell therapy, and cancer vaccines.

Origin

Mesothelin was identified in 1992 by Dr. Ira Pastan and colleagues at the U.S. National Cancer Institute, who recognized it as a cell-surface protein expressed on normal mesothelial cells lining the chest and abdomen, and dramatically overexpressed in mesothelioma and several other cancers. This discovery launched decades of drug development aimed at exploiting mesothelin as a tumor-specific target.

Significance in Asbestos Context

For patients with mesothelioma, mesothelin-targeted therapy represents one of the most actively studied frontiers beyond standard chemotherapy and immunotherapy. Several agents — including anetumab ravtansine, LMB-100 (an immunotoxin), and mesothelin-directed CAR T-cell therapies — have been or are being tested in clinical trials specifically for pleural and peritoneal mesothelioma. Patients should ask their oncologist whether their tumor has been tested for mesothelin expression (often by immunohistochemistry on the biopsy sample) and whether they qualify for a mesothelin-targeted clinical trial, particularly at NCI-designated cancer centers or specialized mesothelioma programs. Documentation of trial participation and tumor marker status (including serum mesothelin/SMRP levels) can also be relevant to medical records used in a legal claim, as they reflect both diagnosis confirmation and the costs and burdens of treatment.

Example Sentence

After her second-line chemotherapy stopped working, Maria's oncologist referred her to a clinical trial of a mesothelin-targeted CAR T-cell therapy at a major cancer center.

Related Terms

Mesothelioma, SMRP (Soluble Mesothelin-Related Peptide), Immunohistochemistry, Immunotherapy, Clinical Trial, CAR T-Cell Therapy

Notes

• Ask your oncologist whether your biopsy was tested for mesothelin expression and whether your serum SMRP level has been measured. Both can determine eligibility for targeted therapies and trials.
• Search ClinicalTrials.gov using terms like 'mesothelin' and 'mesothelioma' to identify open trials, and bring printouts to your oncology appointment to discuss candidacy.
• Preserve all pathology reports, biomarker results, and trial enrollment documents; these become part of the medical record supporting both your treatment history and any legal claim for damages including future medical costs.
• Mesothelin-targeted therapies are still largely investigational. None is yet FDA-approved as standard care for mesothelioma, so insurance coverage and travel logistics for trial participation should be discussed early with a hospital social worker or patient navigator.